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Abstract
Purpose of Review To provide an update of a life span perspective on borderline personality disorder (BPD). We address the life
span course of BPD, and discuss possible implications for assessment, treatment, and research.
Recent Findings BPD first manifests itself in adolescence and can be distinguished reliably from normal adolescent development.
The course of BPD from adolescence to late life is characterized by a symptomatic switch from affective dysregulation,
impulsivity, and suicidality to maladaptive interpersonal functioning and enduring functional impairments, with subsequent
remission and relapse. Dimensional models of BPD appear more age neutral and more useful across the entire life span. There
is a need for age-specific interventions across the life span.
Summary BPD symptoms and impairments tend to wax and wane from adolescence up to old age, and presentation depends on
contextual factors. Our understanding of the onset and early course of BPD is growing, but knowledge of BPD in late life is
limited. Although the categorical criteria of DSM allow for reliable diagnosis of BPD in adolescence, dimensional models appear
both more age neutral, and useful up to late life. To account for the fluctuating expression of BPD, and to guide development and
selection of treatment across the life span, a clinical staging model for BPD holds promise.
Keywords Borderline personality disorder . Life span . Course . Assessment . Treatment
Introduction
The term borderline was first coined by Adolph Stern in 1938
when he identified a “border line group of patients” who “fit
frankly neither into the psychotic nor into the psychoneurotic
group, and are extremely difficult to handle by any psychother-
apeutic method” [1]. The acceptance of borderline personality
disorder (BPD) as a mental disorder in the Diagnostic and
Statistical Manual of Mental Disorders (DSM) 3rd edition in
1980 [2] has stimulated both clinical and scientific attention.
BPD is characterized by impulsivity, self-harm, suicidality, and
emotional and interpersonal instability. DSM-5 [3], like DSM-
IV [4], allows diagnosing BPD under the age of 18, if the
symptoms are pervasive, persistent, not limited to a particular
developmental stage or another mental disorder, and if the
symptoms have been present for at least 1 year.
The categorical DSM concept of BPD, and of personality
disorders in general, has been criticized because of its heteroge-
neity, diagnostic overlap with other disorders, arbitrary threshold,
low reliability, and poor empirical base [5]. Factor analytic stud-
ies found support for one general factor of personality pathology
underlying the nine criteria of BPD [6, 7•]. Moreover, BPD
presents with many comorbid disorders [8]. Because of these
limitations, a growing number of studies focuses on dimensional
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models of personality disorders, such as the AlternativeModel of
Personality Disorders (AMPD) in the DSM-5 and the new per-
sonality disorder concept of the International Classifications of
Diseases 11th Edition (ICD-11) [9]. Both models combine a
severity dimension of personality pathology and a description
of five personality trait domains. In the DSM-5 AMPD, BPD
is defined by negative affectivity, disinhibition and psychoticism,
and several studies have indicated general support for these traits
proposed for BPD [10–12]. Interestingly, ICD-11 does not retain
any specific personality type with the exception of an optional
specifier for “borderline pattern”, operationalized as requiring at
least five out of nine criteria adapted from the DSM-5 criteria for
BPD [9].
Until around 1990, therapeutic nihilism prevailed
concerning the treatment options of BPD [13]. Since then,
beneficial effects have been demonstrated for four compre-
hensive treatments: dialectical behavior therapy (DBT),
mentalization-based treatment (MBT), transference-focused
psychotherapy (TFP), and schema therapy [14, 15].
However, treatment studies have mainly been conducted in
adults between the ages of 25 and 40, and effects remain
modest and unstable at follow-up [14, 15].
Recently, a life span perspective on BPD has been intro-
duced, stressing a lifelong vulnerability of impairments in per-
sonality functioning, including poor mentalizing and impaired
social cognition, along with persisting maladaptive traits like
impulsivity, emotional lability, and separation insecurity [16•].
Traits and impairments are supposed to underpin the phenom-
enological presentation, which may wax and wane throughout
the life span, depending on the complex and changing nature-
nurture interactions from early childhood onwards [16•].
This review provides an update of recent studies and view-
points on a life span perspective on BPD, and discusses pos-
sible implications for assessment, treatment, and research. A
systematic literature search was conducted for articles pub-
lished between January 2014 and January 2019 using the
MEDLINE and PsycINFO databases. The keyword
“Borderline Personality Disorder” combined with “life span”
or its synonyms (“clinical course” and “course”) yielded 145
articles. We included 33 relevant articles (clinical trials or
reviews) on life span perspective, risk factors, assessment,
treatment, and comorbidity of BPD. We excluded articles that
did not contribute to a life span perspective or did not primar-
ily investigate BPD, were case reports, or were written in
languages other than English.
Waxing and Waning Course of BPD
from Childhood to Old Age
Childhood and Adolescence Until the past decade, the vast
majority of our knowledge of BPD concerned diagnosis and
treatment of female patients in early adulthood. Since then,
BPD has also been studied more extensively in adolescents.
This research points out that BPD typically first manifests itself
in adolescence, and that adolescent BPD symptoms can be
distinguished reliably from normative adolescent development
[17]. Moreover, adolescence can be considered a particular sen-
sitive period for BPD pathology to emerge [7•]. Two large
longitudinal studies into the trajectory of BPD from childhood
into young adulthood have shown that BPD pathology has its
onset in the beginning of adolescence [18, 19]. Over 30% of
adult BPD patients reported retrospectively that the onset of
self-injurious behavior was before the age of 13, while in an-
other 30%, this behavior started between the ages of 13 and 17
[20]. From childhood to late adolescence, vulnerable children
destabilize because of a wide range of risk factors [21]. These
include the following: low social economic status, stressful life
events, family adversity, maternal psychopathology, cold, hos-
tile or harsh parenting, exposure to physical or sexual abuse or
neglect, low IQ, high levels of negative affectivity and impul-
sivity, and both internalizing (depression, anxiety, dissociation)
and externalizing (attention-deficit hyperactivity disorder,
oppositional defiant disorder, conduct disorder, substance use)
psychopathology in childhood [21]. These risk factors predict
not only BPD, but a wide range of mental disorders. Prognostic
factors that are specifically associated with a BPD development
in children have not yet been identified [7•, 21].
In adolescence, those individuals who do develop BPD can
reliably be distinguished from those with a healthy development
[22, 23]. Impulsivity, identity issues and affective instability di-
minish in the course of adolescence in healthy youngsters,
whereas these symptoms increase over time in BPD adolescents
[23–25]. The differentiation between healthy development and
BPD becomes more pronounced throughout adolescence [26].
Several studies have found prevalence rates of BPD in
adolescents that are similar to those in adult populations,
1–3% in community-dwelling samples, 33–49% in clini-
cal samples and 11% in outpatient samples [27–29]. This
growing empirical evidence supports that DSM-5, ICD-
11, and several national treatment guidelines allow the
diagnosis of BPD in adolescence [30, 31].
In sum, BPD first emerges in adolescence and symptoms
mainly include impulsive behaviors and affective instability.
Adulthood The course of BPD from adolescence to adulthood
is characterized by a symptomatic switch from predominantly
symptoms of affective dysregulation, impulsivity, and
suicidality to maladaptive interpersonal functioning and en-
during functional impairments, with subsequent periods of
remission and relapse of the full categorical BPD diagnosis,
i.e., meeting the threshold of at least five out of nine DSM-
criteria for BPD [16•, 32, 33]. Longitudinal studies show a
general decrease of full BPD diagnoses from young to middle
adulthood [34, 35]. However, remission of the categorical
BPD diagnosis is commonly followed by relapse, and almost
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half of BPD patients never recover fully, both socially and
vocationally [35, 36]. The course of core features of BPD, as
assessed with retrospective questionnaires, persists through-
out adulthood, such as affective symptoms (chronic dyspho-
ria, anger, and feelings of emptiness), and interpersonal symp-
toms related to fears of abandonment, whereas impulsivity
decreases during adulthood [35–37]. A recent cross-sectional
e-diary study in everyday life showed higher affective insta-
bility prospectively between patients with BPD and healthy
controls, ranging from 14 to 53 years of age, and also showed
that affective instability declinedwith greater age in BPD [38].
Generally, the behavioral symptoms of personality disorders
are less stable than the personality traits associated with BPD
over time [39, 40••]. Although self-injurious and suicidal be-
havior decreases, risk of suicide remains as high as 10% over a
27-year course [37, 41]. Symptoms of BPD wax and wane
over time, and the acute symptoms (e.g., suicidality, self-
harm) change more rapidly and more readily than the temper-
amental symptoms (e.g., dysphoria, feelings of emptiness, and
fear of abandonment) [40••].
BPD in young adulthood predicts a host of negative out-
comes across the life span, including mood, anxiety, eating
and substance use disorders, increased risk for physical ill-
nesses and medical care, reduced quality of life, and reduced
life expectancy [39, 42–45]. As a consequence, many BPD
patients never manage to fully participate in society [34, 46].
Research on predictors of outcome of BPD, based upon the
naturalistic course from adolescence into middle adulthood, has
identified both positive and negative prognostic factors [40••,
46]. Predictors of good outcomes seem to be related mostly to
personal capacity and competence, such as having a higher IQ,
prior good full-time vocational functioning, higher levels of
extraversion, higher levels of agreeableness, and lower levels
of neuroticism. Predictors of poor outcomes are related to great-
er severity and chronicity of the disorder, higher degrees of
comorbidity, and a history of childhood adversity. Non-
recovered patients, which make up about 40%, experience
higher rates of vocational impairment, disability, physical mor-
bidity, and mortality than recovered patients [46].
Late LifeMost longitudinal studies of BPD have not included
people over the age of 50; because of this, our understanding
of the course of BPD into late life is limited [16•]. Cross-
sectional studies suggest a further decline in the prevalence
of BPD frommiddle adulthood to old age [47, 48••]. The only
ongoing longitudinal study into the prevalence and impact of
personality pathology in later life, the SPAN study (St. Louis
Personality and Aging Network), included patients between
the ages of 55 and 64 and found a prevalence rate for BPD of
0.4%, and 0.6% if people with one criterion short for the full
DSM BPD-diagnosis were included [49]. Different explana-
tions can be pointed out for this decline in the prevalence of
BPD. BPD patients, especially those that do not recover, are at
elevated risk of premature death, due to suicide or other causes
[50], related to an unhealthy and sometimes reckless lifestyle
[51]. Furthermore, there are age differences in the expression
of BPD symptoms. In a study among 1447 patients, aged 15–
82 years, a significant decline was found in the externalizing
aspects of BPD symptoms to the age of 50, such as impulsiv-
ity, rule breaking, and emotional turmoil, whereas abandon-
ment fears, selfishness, lack of empathy, and manipulation
remained the same [52]. In the SPAN study, three symptoms
of BPD predicted interpersonal stressful life events: unstable
interpersonal relationships, impulsivity, and chronic feelings
of emptiness [53]. Interestingly, although impulsivity de-
creased with age in BPD, it continued to result in these nega-
tive consequences. BPD has also been found to predict arthri-
tis and heart disease, in which obesity accounts for some of the
variance in this relationship [44, 54].
Recent large-scale IRT analyses on data of the National
Epidemiologic Survey on Alcohol and Related Conditions
(NESARC) among more than 34,000 community-dwelling
people, aged between 19 and 90 years, examined age differ-
ences in the likelihood of endorsing DSM-symptoms of BPD,
when equating for levels of BPD symptom severity [48••].
Older people were consistently less likely to report suicidal/
self-harm behavior than younger respondents and unstable/
intense interpersonal relationships appeared to discriminate
BPD severity better in the youngest age group compared to
the oldest age group, with equivalent levels of BPD severity. It
was further found that the nine DSM BPD-criteria provide
substantially less information (14.7%) in older than in youn-
ger adults. Overall, these findings indicate substantial age-
related differences in BPD symptom expression.
Case studies and clinical experience suggest that features of
BPD can be exacerbated in old age due to contextual changes,
even causing a growing prevalence of BPD in residential care
and psychiatric facilities for the elderly [55–58]. Poor interper-
sonal functioning has caused many old BPD patients to be
estranged from their family and former friends, and when they
become dependent for care, this might re-trigger insecure at-
tachment style issues and fears of abandonment [55]. BPD
symptoms, together with trait neuroticism, appeared unique
predictors of greater suicidal ideation in older adults, over other
personality disorders and normal-range personality traits [59].
In an international Delphi study, experts in personality dis-
orders in older adults reached consensus on the concept of
“late-onset personality disorder”: a personality disorder that
presents for the first time in old age as life events contribute
to the expression of late-onset PD, with the major ones being
death of a spouse or partner and transition to a nursing home
or assisted-living facility [60]. This concept of a personality
disorder emerging in late life is consistent with the ICD-11;
while ICD-10 states that personality disorders tend to be stable
over time, the ICD-11 guideline explicitly states that person-
ality disorders are only “relatively” stable after young
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adulthood, and may change such that a person with a person-
ality disorder in young adulthood no longer meets full criteria
by middle age [9, 61]. In some cases, a person who earlier did
not have a diagnosable personality disorder, may develop one
later in life. Sometimes, emergence of personality disorder in
older adults may be related to the loss of social supports that
had previously helped to compensate for personality distur-
bance. Triggers for late-onset BPD could be the loss of loved-
ones, which might retrigger fears of abandonment.
In sum, a life span perspective on BPD could have important
implications. Instead of being a fixed set of BPD symptoms,
that is invariant throughout the life span, BPD features are
dynamic in nature and their expression depends on contextual
and developmental factors from childhood up to old age [56].
Most BPD patients demonstrate a waxing and waning profile of
impairment throughout adult life with periods of remission and
relapse, while some show stable remission [40••]. This fluctu-
ating nature of BPD should have major impact on our assess-
ment and treatment of BPD throughout the life span.
Assessment Implications of a Life Span
Perspective
A life span perspective has two major implications for assess-
ment of BPD. First, as the current categorical BPD diagnosis
has appeared to be not age-neutral, especially in old age be-
cause of the changing expression of BPD symptoms [48••], it
could be advocated to develop age-specific assessment instru-
ments, or instruments that are age-neutral. For instance, an age-
specific BPD screening instrument could be developed for the
detection of BPD in older adults. The conceptualization of BPD
in the AMPD in DSM-5, with levels of personality functioning
(criterion A) and maladaptive trait dimensions (criterion B), has
been studied for its age-neutrality in community-dwelling older
adults, aged 61 and over [62]. The Short Form of the Severity
Indices of Personality Problems (SIPP-SF), a questionnaire
which can be used to assess criterion A, was found to be rela-
tively age-neutral, as only 6% of the items performed different-
ly for younger and older adults [62]. Of the Personality
Inventory for DSM-5 (PID-5), which is designed to assess cri-
terion B, only 16% of the 25 PID-5 facet-level scales showed
potential age bias [63]. The brief version of this instrument, the
PID-5-BF, appeared to show more age bias, as 25% of the five
trait dimensions functioned differently in older adults [62].
Overall, these findings indicate that the AMPD functions sim-
ilarly in older and younger adults, and is to be preferred over the
current categorical model. Especially criterion A seems to be
more age-neutral than criterion B.
The second implication of a life span perspective on BPD
would be to develop a model that accounts for the development
and possibly chronic course of BPD across the life span.
Therefore, some authors have suggested a clinical staging
model for BPD [56, 64••]. Staging models of diseases originat-
ed in oncology and have been developed for mental disorders,
for instance for psychosis [65]. The first clinical staging model
for BPD was proposed for guiding early intervention in adoles-
cence with BPD and comorbid mood disorders [64••], and was
recently elaborated to assess the severity of BPD impairment
throughout the life span [56]. Clinical staging offers a descrip-
tion of the progression of a disorder along a continuum of
disorder progression, in which progression is typically specified
into five stages, from a pre-morbid stage to an end or chronic
stage [66]. Clinical staging is useful for personalized selection
of appropriate interventions that match with the stage of disease
an individual is in. Although a typical staging profile of BPD
starts in a premorbid stage in childhood and develops into a
subclinical stage in early adolescence and to a first episode of
full BPD in middle or late adolescence, followed by remission
and relapse from middle to late adulthood, other trajectories are
possible. For example, in the case of late onset BPD, people
might live for many decades in a subclinical stage, and only
develop significant problems, andmeet full BPD criteria later in
life. Another stage trajectory might be that BPD wanes into
partial remission in middle adulthood, because of a relationship
with a stable spouse, but re-emerges in old age, due to the
destabilizing effects of bereavement, or physical decline and
admittance to a nursing home. Clinical staging might shift at-
tention towards the degree in which borderline impairment has
progressed and its impact upon age-specific developmental
tasks across the life span [56]. Adopting a clinical staging mod-
el across the life span could be helpful to design interventions
tailored to the stage of BPD.
Treatment Implications of a Life Span
Perspective
As said, most of our knowledge of psychotherapeutic treat-
ment of BPD comes from studies conducted in adults between
the ages of 25 and 40 years, and these treatment models are
focused on the acute episodes of the disorder. Typically, spe-
cialized treatments are offered rather late in the course of BPD,
tend to be costly and lengthy, and available only to a subgroup
of BPD patients who do seek help and manage to attend to the
treatment setting [67]. Furthermore, as most existing treat-
ments for BPD focus largely on the acute symptoms of self-
harm and impulsivity, it might be fruitful to develop interven-
tions that target underlying impairments, such as the affective
symptoms, and improve social and vocational functioning, as
they have been associated with recovery [40••, 46].
A life span perspective, adopting a clinical staging model,
could be especially helpful to design interventions tailored to
the stage of BPD. The earliest intervention is prevention of the
onset of BPD by broad prevention programs. An example is
preventing the transgenerational transmission of BPD, like
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mentalization-based treatment for parents (MBT-P) [68].
Early treatment programs target adolescents with emerging
signs of BPD, such as Helping Young People Early-
Cognitive Analytic Therapy (HYPE-CAT) [69]. Specific
treatments have been developed for adolescents, such as
DBT for adolescents (DBT-A) [70], and MBT for adolescents
(MBT-A) [71]. Early intervention programs might also be
developed for people with subthreshold BPD in late adulthood
to prevent emerging late onset BPD, and for older adults with
a first episode of acute BPD. Such treatment programs could
focus on helping the older patient to adapt to age-specific
stressors, like the death of a spouse or coping with becoming
dependent for care. Adaptations of standard treatment pro-
grams, like MBT, DBT, TFP, and schema therapy, are needed
for BPD in late life, and the first trial of schema therapy for
BPD in older adults is currently being conducted [72]. Finally,
specific treatment programs are needed for the frail and “old-
old” BPD patients, which could be focused on staff under-
standing and behavioral management in care settings.
Research into the efficacy and tolerability of symptom-
based pharmacotherapy for BPD [73, 74] consists of relatively
few trials, and is based on findings in adults up to 50 years of
age, and the quality of these studies is generally low [74].
There is a lack of research on pharmacotherapy for BPD in
adolescence and in older adults. Especially in older adults,
polypharmacy and changing pharmacodynamics and pharma-
cokinetics are complicating factors in pharmacotherapy in
BPD, which can lead to side effects and interactions [75].
Implications for Research
A life span perspective on BPD also helps defining new re-
search objectives. One such goal would be to stop examining
distal risk factors that are indicative for later general psychopa-
thology and shed light on which precursors in childhood and
adolescence are specific for BPD [7•], and what personal and
contextual characteristics determine a ‘high-risk’ profile for
chronic BPD. In doing so, we would be able to identify which
children are at ultrahigh risk for the development of BPD.
Another major research implication of a life span perspective
on BPD is to investigate whether the new dimensional models
of DSM and ICD-11 indeed are capable of capturing the chang-
ing expression of BPD across the entire life span [16•].
Assessment of the AMPD with the SIPP-Sf and the PID-5
appears to be relatively age-neutral, except for the brief version
of the PID-5. Therefore, the PID-BF should be examined in
other populations, especially in clinical populations.
Furthermore, research could focus on the applicability of a
life span clinical staging model for BPD, and on the added
value of this model for selecting more appropriate
interventions. The focus in treatment studies has been for too
long on comparing specialized psychotherapies in adult BPD
patients, but should turn to examining generic working mecha-
nisms. Furthermore, there is a need to adapt specific treatment
approaches throughout the life span, as they were designed for
(young) adults and do not match with the needs of adolescents
and older adults. Early intervention programs need to be devel-
oped and assessed for their efficacy across the entire life span.
In the long run, early detection and intervention may prevent to
a large extent that BPD evolves to a chronic stage in many
cases, but for now we need to develop effective treatments for
BPD in late life. This involves the adaptation of integrative
treatments for older adults, but also behavioral management
programs for old BPD patients in residential and home care.
Conclusions
There is accumulating knowledge on the onset and course of
BPD across the life span. Our understanding of the onset and
early course of BPD is growing, but knowledge of BPD in late
life is still very limited. BPD first manifests itself in adoles-
cence, and can be distinguished reliably from normative ado-
lescent development. BPD symptoms and impairments contin-
ue to wax and wane up to old age, and their expression depends
on contextual and developmental factors. The course of BPD
from adolescence to adulthood is characterized by a symptom-
atic switch from predominantly symptoms of affective instabil-
ity and impulsivity to maladaptive interpersonal functioning
and enduring functional impairments, with subsequent periods
of remission and relapse of the full categorical BPD diagnosis.
Although the categorical criteria of DSM allow for reliable
diagnosis of BPD in adolescence, dimensional models appear
both more age neutral, and especially more useful in later life.
To guide early intervention and better treatment selection across
the life span a clinical staging model for BPD holds promise.
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